Industry Leading TCR Pipeline Targeting Solid and Hematologic Cancers
Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development.
SPEAR® T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO* are progressing through clinical studies in multiple cancer types.